Cargando…

Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection

Clostridium difficile infection (CDI) is the most common health care-acquired infection associated with high hospital expenditures. The incidence of subsequent recurrent CDI increases with prior episodes of CDI, 15%–35% risk after primary CDI to 35%–65% risk after the first recurrent episode. Recurr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Navalkele, Bhagyashri D, Chopra, Teena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779312/ https://www.ncbi.nlm.nih.gov/pubmed/29403263 http://dx.doi.org/10.2147/BTT.S127099

Ejemplares similares

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
por: Gerding, Dale N, et al.
Publicado: (2018)

Bezlotoxumab Therapy for Recurrent Clostridium difficile Infection in an Ulcerative Colitis Patient
por: Fein, Aaron, et al.
Publicado: (2022)

The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review
por: Thandavaram, Abhay, et al.
Publicado: (2022)

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection
por: Džunková, Mária, et al.
Publicado: (2016)

Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment
por: Shen, Judong, et al.
Publicado: (2020)

Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
por: Alonso, Carolyn D, et al.
Publicado: (2018)

Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection
por: Escudero-Sánchez, Rosa, et al.
Publicado: (2020)

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients
por: Johnson, Tanner M, et al.
Publicado: (2021)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

789. Evaluation of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence
por: Johnson, Tanner M, et al.
Publicado: (2020)

Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI
por: Navalkele, Bhagyashri D., et al.
Publicado: (2016)

505. Bezlotoxumab Reduces Recurrence of Clostridium difficile Infection in Immunocompromised Patients: Early Experience at a Tertiary Care Center
por: Askar, Sally, et al.
Publicado: (2018)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
por: Dorr, Mary Beth, et al.
Publicado: (2017)

Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland
por: Oksi, Jarmo, et al.
Publicado: (2019)

Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
por: Mileto, Steven J., et al.
Publicado: (2022)

2117. Catheter-related Bacteremia in Hemodialysis Patients on Antibiotic Lock Therapy: Are Antibiotic Locks Ineffective?
por: Krishna, Amar, et al.
Publicado: (2018)

729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients
por: Perreault, Sarah, et al.
Publicado: (2020)

Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain
por: Salavert, Miguel, et al.
Publicado: (2018)

Impact of a Multidisciplinary Infection Prevention Initiative on Central Line and Urinary Catheter Utilization in a Long-term Acute Care Hospital
por: Chandramohan, Suganya, et al.
Publicado: (2018)

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
por: Prabhu, Vimalanand S, et al.
Publicado: (2017)

1653 Results of a Treatment Protocol Encouraging First-Line Use of Fidaxomicin for Select Patients with Clostridium difficile Infection (CDI)
por: Navalkele, Bhagyashri, et al.
Publicado: (2014)

Genome Wide Analysis Reveals Host Genetic Variants that Associate with Reduction in Clostridium difficile Infection Recurrence (rCDI) in Patients Treated with Bezlotoxumab
por: Shaw, Peter, et al.
Publicado: (2017)

The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021
por: Hyte, Melanie L., et al.
Publicado: (2022)

Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience
por: Olmedo, María, et al.
Publicado: (2022)

501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers
por: Hengel, Richard L, et al.
Publicado: (2018)

Bezlotoxumab in Patients with a Primary Clostridioides difficile Infection: A Literature Review
por: Granata, Guido, et al.
Publicado: (2022)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
por: Hengel, Richard L, et al.
Publicado: (2020)

1496. Bezlotoxumab Administered at the End of a Suppressive Drug Regimen for Patients with Multiply Recurrent Clostridioides difficile Infection
por: Tan, Xing, et al.
Publicado: (2019)

Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection
por: Förster, Beatrix, et al.
Publicado: (2018)

Recent Respiratory Tract Infection and Additional Surgeries Increase Risk for Surgical Site Infection in Total Joint Arthroplasty: A Retrospective Analysis of 2255 Patients
por: Navalkele, Bhagyashri, et al.
Publicado: (2017)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials
por: Alhifany, Abdullah A, et al.
Publicado: (2019)

Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention
por: Song, Jung Hoon, et al.
Publicado: (2019)

Tea and Recurrent Clostridium difficile Infection
por: Oman Evans II, Martin, et al.
Publicado: (2016)

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013)

Recent Progress for the Effective Prevention and Treatment of Recurrent Clostridium difficile Infection
por: Ramsay, Isobel, et al.
Publicado: (2018)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials
por: Bouza, Emilio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9aj97uahfkiv7eq615cnbg48pr